Comparative Performance of INVU™ Versus Intrauterine Pressure Catheter (IUPC) in Uterine Contractions Monitoring of Pregnant Women.

Healthy, Pregnant Women Clinical Trial

Official title:

Clinical Study Evaluating the Safety of Invu ™ and Comparative Performance of Invu ™ Versus IUPC in Prenatal Monitoring of Pregnant Subjects With Uterine Contractions.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03889405
• Other study ID #: CLP-2000
• Status: Completed
• Phase: N/A
• Start date: April 9, 2019
• Est. completion date: January 31, 2020

Study information

• Verified date: January 2021
• Source: Nuvo-Group, Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this research is to assess the agreement between INVU™ and IUPC (the gold standard) during prenatal monitoring of uterine contractions and to assess the safety of INVU™. Additional information comparing INVU™ to TOCO (the standard of care) was also collected.

Description:

This multi-center, prospective, comparative, open-label study will be performed in two steps:

A training step where up to 40 subjects will be enrolled to confirm uterine contraction performance level.

In the second, validation step, the performance of the uterine contraction detection algorithm will be validated. The validation phase will involve up to 80 subjects.

Sub-study will be implemented in the sites that will monitor the uterine activity of the subjects with TOCO, in addition to INVU™ and IUPC.

Following the screening process, participants subject will undergo continuous recording of the uterine contraction and the fetal heart rate (FHR) for 30 to 60 min using INVU™, Cardiotocograph ((TOCO / CTG), and Intrauterine Pressure Catheters (IUPC). The collected data will be downloaded and comprehensive analysis of the values will be performed offline. Each participant will undergo continuous monitoring by the medical team to identify any safety issue, including but not limited to irritation, sensitization, and potential harmful misuse.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: January 31, 2020
• Est. primary completion date: January 31, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Female age between 18-50

• Gestational age =32 + 0 weeks

• Singleton gestation

• Ability to understand and sign informed consent

• The subject is within the first stage labor, including early, active and transition phases (cervix is dilated up to 10 cm)

• The subject has an IUPC in place for clinical contraction monitoring

• Exclusion Criteria:

• BMI =50 and 15= prior pregnancy (Body Mass Index)

• Multiple gestation

• Uncontrolled Hypertension

• Known fetal Anomaly (i.e. major structural)

• Subjects with skin problems in the abdominal area (such as flesh wounds, cuts in the skin, skin rashes, etc.)

• Subjects with implanted electronic devices (pacemaker, defibrillator, etc.)

• Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study

• Subject who is within the second stage labor (cervix is fully dilated to 10 cm or going into the second stage of labor or more)

Related Conditions & MeSH terms

• Healthy, Pregnant Women

Intervention

Device:
• INVU™
The subject will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) for 30 to 60 min using INVU™.
• IUPC
The study participants will undergo continuous recording of the uterine contractions by IUPC.
• TOCO
Some of the study participants will undergo continuous recording of the uterine contractions and the fetal heart rate (FHR) by TOCO as well.

Locations

Country	Name	City	State
United States	University of Arkansas for Medical Sciences	Little Rock	Arkansas
United States	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Nuvo-Group, Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of the agreement between INVU™ and IUPC (the gold standard) during monitoring of uterine contractions as well as the agreement between Cardiotocography (TOCO) and IUPC, where applicable.	Three blinded assessors will review the uterine contractions output data (the recordings) from the monitoring devices and determine for each time point whether a contraction occurred. The assessors will not have visibility to the source of the recorded data. Each assessor will review the sessions in a randomized order, while the evaluation will include: a contraction start point, peak, and endpoint. The actual presence of a contraction will be determined by the IUPC.	30-60 minutes per participant